Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen's latest ADC
Eight and a half months since its last OK for Xywav, Jazz Pharmaceuticals has won priority review for a new indication with the drug. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
